New breast cancer drug tested against standard treatment in phase 3 trial
Disease control
Terminated
This study compares a new drug called EG1206A to the approved drug Perjeta, both given with trastuzumab and chemotherapy, for people with HER2-positive early breast cancer. The treatment is given before and after surgery to see if the new drug works as well as the standard one. T…
Phase: PHASE3 • Sponsor: EirGenix, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC